|
1) Holst JJ. The physiology of glucagons-like peptide 1. Physiol Rev. 2007; 87: 1409-39
|
|
|
|
2) Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differencis. J Diabetes Invest. 2010; 1: 8-23
|
|
|
|
|
|
3) Knudsen LB, Mielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43: 1664-9
|
|
|
|
|
|
4) Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glipenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010; 26: 1013-22
|
|
|
|
|
|
5) Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010; 12: 341-7
|
|
|
|
|
|
6) Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of Exendin-4, an Exendin-3 analogue, from Heloderma suspectum Venom. J Biol Chem. 1992; 267: 7402-5
|
|
|
|
|
|
7) Goke R, Fehmann HC, Lin T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secretingβ-cells. J Biol Chem. 1993; 268: 19650-5
|
|
|
|
|
|
8) Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010; 164: 58-64
|
|
|
|
|
|
9) Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628-35
|
|
|
|
|
|
10) Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-91
|
|
|
|
|
|
11) Defronzo RA, Rather RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28: 1092-100
|
|
|
|
|
|
12) Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest. 2011; 2: 210-7
|
|
|
|
|
|
13) Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 daibetes. Diabetes Care. 2011; 34: 2041-7
|
|
|
|
|
|
14) Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves β-cell function, compared with insuline glargine, in metformin-treated type 2 diabetic patients. Diabetes Care. 2009; 32: 762-8
|
|
|
|
|
|
15) Vilsboll T, Brock B, Perrildt H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008; 25: 152-6
|
|
|
|
|
|
16) Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with addingrosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26: 268-78
|
|
|
|
|
|
17) Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. The LEAD (Liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32: 84-90
|
|
|
|
|
|
18) Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373: 473-81
|
|
|
|
|
|
19) Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met＋TZD). Diabetes Care. 2009; 32: 1224-30
|
|
|
|
|
|
20) Russel-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformine and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met＋SU): a randomised controlled trial. Diabetologia. 2009; 52: 2046-55
|
|
|
|
|
|
21) Astrup A, Rossner S, Gaal LV, et al. Effects of liraglutide in the treatment of obesity: a rondomised, double-blind, placebo-controlled study. Lancet. 2009; 374: 1606-16
|
|
|
|
|
|
22) Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009; 11: 1163-72
|
|
|
|
|
|
23) Seino Y, Rasmussen MF, Zdravkovic M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomised, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008; 81: 161-8
|
|
|
|
|
|
24) Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275-86
|
|
|
|
|
|
25) Horton ES, Silberman C, Davis K, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010; 33: 1759-65
|
|
|
|
|
|
26) Sebokova E, Christ AD, Wang H, et al. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. Endocrinology. 2010; 151: 2474-82
|
|
|
|
|
|
27) Dong JZ, Shen Y, Zhang J, et al. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes. Endocrinology. 2010; 151: 2474-82
|
|
|
|
|
|
28) Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 4810-7
|
|
|
|
|
|
29) St Onge EL, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther. 2010; 10: 801-6
|
|
|
|
|
|
30) Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372: 1240-50
|
|
|
|
|
|
31) Bergenstal R, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010; 376: 431-9
|
|
|
|
|
|
32) Diamant M, Gaal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010; 375: 2234-43
|
|
|
|
|
|
33) Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141: 150-6
|
|
|
|
|
|
34) Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med. 2008; 358: 1970-2
|
|
|
|
|